- Home
- XXI vs BHC Comparison
XXI vs BHC Comparison
Compare XXI & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XXI | BHC |
|---|---|---|
| Founded | 2025 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | 2026 | 1996 |
Fundamental Metrics
Financial Performance| Metric | XXI | BHC |
|---|---|---|
| Price | $5.59 | $6.49 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 1.4M | ★ 1.7M |
| Earning Date | 11-11-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 423.08 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $8,724,000,000.00 |
| Revenue This Year | N/A | $6.05 |
| Revenue Next Year | N/A | $0.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.15 | $4.33 |
| 52 Week High | $11.49 | $8.00 |
Technical Indicators
Market Signals| Indicator | XXI | BHC |
|---|---|---|
| Relative Strength Index (RSI) | 41.26 | 65.63 |
| Support Level | $5.02 | $5.44 |
| Resistance Level | $5.71 | $7.04 |
| Average True Range (ATR) | 0.33 | 0.25 |
| MACD | -0.10 | 0.06 |
| Stochastic Oscillator | 10.25 | 91.96 |
Price Performance
Historical ComparisonAbout XXI Twenty One Capital Inc. Class A Common Stock
Twenty One Capital Inc is engaged in the Bitcoin-related business lines. It engages in two principal activities: actively accumulating Bitcoin and managing its Bitcoin holdings, and commencing development of educational materials and branded content intended to drive increased institutional and retail investor Bitcoin literacy.
About BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.